查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1933313

全球抗病毒藥物市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的考察、未來預測（2026-2034）

Antiviral Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 130 Pages | 商品交期: 請詢問到貨日

價格

抗病毒藥物市場成長因素

預計全球抗病毒藥物市場在預測期內將穩定成長。市場規模2025年達到423.4億美元，2026年達到442.1億美元，2034年將成長至543.7億美元。這意味著2026年至2034年的年複合成長率（CAGR）為3.64%。北美地區佔據市場主導地位，到2025年達到38.78%的市場佔有率，這主要歸功於該地區擁有眾多大型製藥公司、HIV等病毒感染的高發生率以及美國食品藥品監督管理局（FDA）批准的多種藥物。

病毒是由RNA或DNA組成，外層包裹著蛋白質外殼的感染性顆粒，能夠感染人類細胞並引起病毒性疾病。病毒感染是嚴重的公共衛生問題，會導致顯著的發病率和死亡率。抗病毒藥物的作用機轉是抑制病毒複製或恢復宿主細胞的正常功能。目前已知有超過1000種病毒感染人類，約佔人類傳染病的60%，因此對有效抗病毒治療的需求仍然很高。然而，病毒的快速複製和缺乏快速診斷試劑給藥物研發帶來了挑戰。

市場驅動因素

該市場的主要驅動因素是愛滋病毒和流感在全球範圍內的蔓延。根據世界衛生組織統計，截至2018年，全球約有3,790萬人感染愛滋病毒，77萬人死於此病。加強愛滋病毒監測和改進診斷工具擴大符合抗病毒療法條件的患者群體。同樣，流感快速診斷也促進了抗病毒藥物需求的成長。

重磅療法的推出進一步加速了市場成長。諸如Biktarvy（Gilead Sciences）和Trumeq（GlaxoSmithKline）等藥物徹底改變了抗逆轉錄病毒療法，提高了患者的治療效果和依從性。 Biktarvy於2024年2月獲批，主要針對接受抗逆轉錄病毒療法的約2100萬HIV感染者，能夠顯著增強免疫系統。

市場限制因子

抗病毒藥物價格昂貴，且在發展中國家取得途徑有限，這些都阻礙了其廣泛應用。此外，抗藥性病毒株的出現也要求持續進行研發工作，以開發下一代療法。

市場區隔

依藥物類別劃分：

  • 到2026年，複方製劑將佔據63.32%的市場佔有率，主要得益於Genvoya、Mavyret和Triumeq等品牌。
  • 由於Tivicay和Isentress等高效且耐受性良好的藥物，整合酶抑制劑預計將實現成長。
  • 其他類別包括蛋白酶抑制劑、聚合酶抑制劑、逆轉錄酶抑制劑和其他藥物。

依疾病劃分：

  • 到2026年，HIV將佔據82.04%的市場佔有率，由於其高盛行率和有利的健保償付政策，HIV將繼續保持領先地位。
  • 其他適應症包括肝炎、流感、皰疹、輪狀病毒和其他病毒感染。政府參與愛滋病防治宣傳和預防計畫也促進了市場成長。

依通路劃分：

  • 由於政府支持、有利的償付制度和完善的供應鏈網路，醫院藥房佔據市場主導地位。
  • 到2026年，零售藥局將佔據47.66%的市場佔有率，這得益於非處方藥和仿製抗病毒藥物的普及。
  • 由於線上通路的便利性和可近性提高，預計線上通路將實現顯著成長。

區域分析

北美：到2025年，營收達到164.2億美元，主要受美國市場驅動。愛滋病毒感染率高、實力雄厚的製藥公司以及重磅療法的核准是推動美國市場成長的關鍵因素。預計到2026年，美國市場規模將達到142.2億美元。

亞太地區：由於印度和日本醫藥基礎設施的改善、病毒疫情的頻繁爆發以及政府在疾病控制方面的積極參與，預計該地區將呈現最高的年複合成長率。到2026年，日本市場規模預計將達到18.6億美元，中國市場規模將達27.2億美元，印度市場規模將達25.7億美元。

歐洲：有利的償付制度、新產品的推出以及政府的積極支持推動了市場成長。預計到2026年，英國和德國市場規模將分別達到 17.1億美元和 27.1億美元。

拉丁美洲、中東和非洲：預計成長將受到醫療基礎設施改善、宣傳活動以及政府主導的目的是滿足有效抗病毒療法未滿足需求的舉措的推動。

目錄

第1章 引言

第2章 執行摘要

第3章 市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機會

第4章 主要考察

  • 主要行業趨勢
  • 主要趨勢：併購等
  • 主要國家的監管和償付情況
  • 主要國家主要病毒性疾病的流行情況（2025年）
  • 新產品上市

第5章 全球抗病毒藥物市場分析：洞察與預測（2021-2034）

  • 關鍵分析/摘要
  • 市場分析、洞察與預測：依疾病分類
    • 肝炎
    • 人類免疫缺乏病毒（HIV）
    • 流感
    • 其他
  • 市場分析、洞察與預測：依藥物類別
    • 整合酶抑制劑
    • 聚合酶抑制劑
    • 蛋白酶/轉錄酶抑制劑
    • 複方藥物
    • 逆轉錄酶抑制劑
    • 其他
  • 市場分析、洞察與預測：依通路
    • 醫院藥房
    • 零售藥房
    • 線上渠道
  • 市場分析，洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章 北美抗病毒藥物市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第7章 歐洲抗病毒藥物市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞半島
    • 其他地區歐洲

第8章 亞太地區抗病毒藥物市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 東南亞
    • 亞太其他地區

第9章 拉丁美洲抗病毒藥物市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第10章 中東與非洲抗病毒藥物市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • GCC國家
    • 南非
    • 中東和非洲其他地區

第11章 競爭分析

  • 主要行業趨勢
  • 全球市場佔有率分析（2018）
  • 競爭概覽
  • 主要公司比較分析
  • 公司簡介
  • Gilead Sciences
  • GlaxoSmithKline
  • Abbvie, Inc.
  • Merck &Co., Inc.
  • Bristol-Myers Squibb Company
  • Janssen Pharmaceuticals, Inc.
  • Mylan N.V.
  • Novartis AG

第12章 策略建議

Product Code: FBI102190

Growth Factors of antiviral drugs Market

The global antiviral drugs market is expected to experience steady growth over the forecast period. In 2025, the market was valued at USD 42.34 billion, projected to reach USD 44.21 billion in 2026, and expand to USD 54.37 billion by 2034, representing a CAGR of 3.64% from 2026-2034. North America dominated the market in 2025 with a 38.78% share, attributed to the presence of leading pharmaceutical companies, high prevalence of viral infections such as HIV, and multiple USFDA drug approvals.

Viruses are infectious particles containing RNA or DNA enclosed in a protein coat, capable of infecting human cells and causing viral diseases. Viral infections are a significant public health concern, responsible for considerable morbidity and mortality. Antiviral drugs work by inhibiting viral replication or restoring the normal function of host cells. With over a thousand viruses infecting humans and accounting for approximately 60% of human infections, the demand for effective antiviral therapies remains high. However, rapid virus replication and lack of quick diagnostic reagents present challenges in drug development.

Market Drivers

The market is primarily driven by the rising prevalence of HIV and influenza globally. According to WHO, approximately 37.9 million people were living with HIV in 2018, with 770,000 deaths attributed to the disease. Enhanced HIV surveillance and improved diagnostic tools have expanded the patient pool for antiretroviral therapies. Similarly, the rapid diagnosis of influenza has increased the demand for antiviral drugs.

The introduction of blockbuster therapeutics has further fueled market growth. Drugs like Biktarvy (Gilead Sciences) and Triumeq (GlaxoSmithKline) have revolutionized antiretroviral therapy, improving patient outcomes and treatment adherence. Biktarvy, approved in February 2024, targets populations living with HIV, where approximately 21 million people receive antiretroviral therapy, significantly strengthening immune systems.

Market Restraints

High costs of antiviral medications and limited access in developing countries pose barriers to widespread adoption. Additionally, the emergence of resistant viral strains requires ongoing R&D to develop next-generation therapies.

Market Segmentation

By Drug Class:

  • Combination drugs dominate with a 63.32% share in 2026, driven by brands like Genvoya, Mavyret, and Triumeq.
  • Integrase inhibitors are projected to expand due to potent drugs like Tivicay and Isentress, favored for high efficacy and tolerability.
  • Other classes include protease inhibitors, polymerase inhibitors, reverse transcriptase inhibitors, and miscellaneous agents.

By Disease Indication:

  • HIV dominates with an 82.04% share in 2026, owing to its high prevalence and supportive reimbursement policies.
  • Other indications include hepatitis, influenza, herpes, rotavirus, and other viral infections. Government participation in HIV awareness and preventive programs also supports market growth.

By Distribution Channel:

  • Hospital pharmacies dominate due to government support, favorable reimbursement, and organized supply networks.
  • Retail pharmacies hold a 47.66% share in 2026, supported by OTC and generic antiviral availability.
  • Online channels are projected to grow significantly due to increased accessibility and convenience.

Regional Analysis

North America: Revenue of USD 16.42 billion in 2025, led by U.S. market, driven by HIV prevalence, strong pharmaceutical presence, and approvals of blockbuster therapies. U.S. market projected to reach USD 14.22 billion by 2026.

Asia Pacific: Expected to show the highest CAGR, driven by improved pharmaceutical infrastructure in India and Japan, frequent viral outbreaks, and government participation in disease management. Markets in Japan, China, and India are projected at USD 1.86 billion, USD 2.72 billion, and USD 2.57 billion by 2026, respectively.

Europe: Market growth supported by favorable reimbursement, new product launches, and active government support. UK and Germany projected at USD 1.71 billion and USD 2.71 billion by 2026, respectively.

Latin America & Middle East/Africa: Growth driven by improved healthcare infrastructure, awareness campaigns, and government initiatives to address unmet needs for effective antiviral therapies.

Competitive Landscape

Key players include Gilead Sciences, GlaxoSmithKline, AbbVie, Merck & Co., Bristol-Myers Squibb, Janssen Pharmaceuticals, Mylan, and Novartis.

Notable Developments:

  • July 2021: Vaxart, Inc. licensed Vapendavir to Altesa Biosciences for clinical-stage antiviral development.
  • June 2021: Pardes Biosciences and FS Development merged to advance oral antivirals against SARS-CoV-2.
  • March 2021: Pfizer initiated Phase 1 study for oral protease inhibitor PF-07321332 targeting SARS-CoV-2.
  • January 2021: ViiV Healthcare received FDA approval for Cabenuva, reducing HIV treatment dosing from 365 to 12 days annually.

Conclusion

The antiviral drugs market is projected to grow from USD 42.34 billion in 2025 to USD 54.37 billion by 2034, at a CAGR of 3.64%. Market growth is primarily driven by the high prevalence of HIV and influenza, introduction of blockbuster drugs, and increasing government support for public health initiatives. Hospital pharmacies continue to dominate distribution, while emerging online channels enhance accessibility. North America maintains the largest market share, while Asia Pacific is expected to witness the highest growth due to expanding healthcare infrastructure and rising viral disease burden. The presence of established pharmaceutical players and robust pipeline developments are anticipated to shape the competitive landscape, ensuring continued growth in antiviral therapeutics worldwide.

Segmentation By Drug Class

  • Protease Inhibitors
  • Polymerase Inhibitors
  • Integrase Inhibitors
  • Reverse Transcriptase Inhibitors
  • Combination Drugs
  • Others

By Disease Indication

  • Hepatitis
  • Human Immunodeficiency Virus (HIV)
  • Influenza
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Channel

By Geography

  • North America (U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
  • Latin America (Brazil, Mexico, and Rest of Latin America)
  • Middle East and Africa (South Africa, GCC, and Rest of Middle East & Africa)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities

4. Key Insights

  • 4.1. Key Industry Trends
  • 4.2. Recent industry developments such as mergers & acquisitions
  • 4.3. regulatory and reimbursement scenario for key countries
  • 4.4. Prevalence of Key viral diseases, in major countries, 2025
  • 4.5. New Product Launches

5. Global Antiviral Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Key Findings / Summary
  • 5.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 5.2.1. Hepatitis
    • 5.2.2. Human Immunodeficiency Virus (HIV)
    • 5.2.3. Influenza
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Drug Class
    • 5.3.1. Integrase Inhibitors
    • 5.3.2. Polymerase Inhibitors
    • 5.3.3. Protease Inhibitors
    • 5.3.4. Combination Drugs
    • 5.3.5. Reverse Transcriptase Inhibitors
    • 5.3.6. Others
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacy
    • 5.4.2. Retail Pharmacy
    • 5.4.3. Online Channel
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Antiviral Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Key Findings / Summary
  • 6.2. Market Analysis - By Disease Indication
    • 6.2.1. Hepatitis
    • 6.2.2. Human Immunodeficiency Virus (HIV)
    • 6.2.3. Influenza
    • 6.2.4. Others
  • 6.3. Market Analysis - By Drug Class
    • 6.3.1. Integrase Inhibitors
    • 6.3.2. Polymerase Inhibitors
    • 6.3.3. Protease Inhibitors
    • 6.3.4. Combination Drugs
    • 6.3.5. Reverse Transcriptase Inhibitors
    • 6.3.6. Others
  • 6.4. Market Analysis - By Distribution Channel
    • 6.4.1. Hospital Pharmacy
    • 6.4.2. Retail Pharmacy
    • 6.4.3. Online Channel
  • 6.5. Market Analysis - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Antiviral Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Key Findings / Summary
  • 7.2. Market Analysis - By Disease Indication
    • 7.2.1. Hepatitis
    • 7.2.2. Human Immunodeficiency Virus (HIV)
    • 7.2.3. Influenza
    • 7.2.4. Others
  • 7.3. Market Analysis - By Drug Class
    • 7.3.1. Integrase Inhibitors
    • 7.3.2. Polymerase Inhibitors
    • 7.3.3. Protease Inhibitors
    • 7.3.4. Combination Drugs
    • 7.3.5. Reverse Transcriptase Inhibitors
    • 7.3.6. Others
  • 7.4. Market Analysis - By Distribution Channel
    • 7.4.1. Hospital Pharmacy
    • 7.4.2. Retail Pharmacy
    • 7.4.3. Online Channel
  • 7.5. Market Analysis - By Country/Sub-region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Spain
    • 7.5.5. Italy
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Antiviral Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Key Findings / Summary
  • 8.2. Market Analysis - By Disease Indication
    • 8.2.1. Hepatitis
    • 8.2.2. Human Immunodeficiency Virus (HIV)
    • 8.2.3. Influenza
    • 8.2.4. Others
  • 8.3. Market Analysis - By Drug Class
    • 8.3.1. Integrase Inhibitors
    • 8.3.2. Polymerase Inhibitors
    • 8.3.3. Protease Inhibitors
    • 8.3.4. Combination Drugs
    • 8.3.5. Reverse Transcriptase Inhibitors
    • 8.3.6. Others
  • 8.4. Market Analysis - By Distribution Channel
    • 8.4.1. Hospital Pharmacy
    • 8.4.2. Retail Pharmacy
    • 8.4.3. Online Channel
  • 8.5. Market Analysis - By Country/Sub-region
    • 8.5.1. Japan
    • 8.5.2. China
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Antiviral Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Key Findings / Summary
  • 9.2. Market Analysis - By Disease Indication
    • 9.2.1. Hepatitis
    • 9.2.2. Human Immunodeficiency Virus (HIV)
    • 9.2.3. Influenza
    • 9.2.4. Others
  • 9.3. Market Analysis - By Drug Class
    • 9.3.1. Integrase Inhibitors
    • 9.3.2. Polymerase Inhibitors
    • 9.3.3. Protease Inhibitors
    • 9.3.4. Combination Drugs
    • 9.3.5. Reverse Transcriptase Inhibitors
    • 9.3.6. Others
  • 9.4. Market Analysis - By Distribution Channel
    • 9.4.1. Hospital Pharmacy
    • 9.4.2. Retail Pharmacy
    • 9.4.3. Online Channel
  • 9.5. Market Analysis - By Country/Sub-region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Antiviral Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Key Findings / Summary
  • 10.2. Market Analysis - By Disease Indication
    • 10.2.1. Hepatitis
    • 10.2.2. Human Immunodeficiency Virus (HIV)
    • 10.2.3. Influenza
    • 10.2.4. Others
  • 10.3. Market Analysis - By Drug Class
    • 10.3.1. Integrase Inhibitors
    • 10.3.2. Polymerase Inhibitors
    • 10.3.3. Protease Inhibitors
    • 10.3.4. Combination Drugs
    • 10.3.5. Reverse Transcriptase Inhibitors
    • 10.3.6. Others
  • 10.4. Market Analysis - By Distribution Channel
    • 10.4.1. Hospital Pharmacy
    • 10.4.2. Retail Pharmacy
    • 10.4.3. Online Channel
  • 10.5. Market Analysis - By Country/Sub-region
    • 10.5.1. GCC Countries
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Key Industry Developments
  • 11.2. Global Market Share Analysis (2018)
  • 11.3. Competition Dashboard
  • 11.4. Comparative Analysis - Major Players
  • 11.5. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 11.5.1. Gilead Sciences
      • 11.5.1.1. Overview,
      • 11.5.1.2. Products & services,
      • 11.5.1.3. SWOT analysis,
      • 11.5.1.4. Recent developments,
      • 11.5.1.5. strategies,
      • 11.5.1.6. financials (based on availability)
    • 11.5.2. GlaxoSmithKline
      • 11.5.2.1. Overview,
      • 11.5.2.2. Products & services,
      • 11.5.2.3. SWOT analysis,
      • 11.5.2.4. Recent developments,
      • 11.5.2.5. strategies,
      • 11.5.2.6. financials (based on availability)
    • 11.5.3. Abbvie, Inc.
      • 11.5.3.1. Overview,
      • 11.5.3.2. Products & services,
      • 11.5.3.3. SWOT analysis,
      • 11.5.3.4. Recent developments,
      • 11.5.3.5. strategies,
      • 11.5.3.6. financials (based on availability)
    • 11.5.4. Merck & Co., Inc.
      • 11.5.4.1. Overview,
      • 11.5.4.2. Products & services,
      • 11.5.4.3. SWOT analysis,
      • 11.5.4.4. Recent developments,
      • 11.5.4.5. strategies,
      • 11.5.4.6. financials (based on availability)
    • 11.5.5. Bristol-Myers Squibb Company
      • 11.5.5.1. Overview,
      • 11.5.5.2. Products & services,
      • 11.5.5.3. SWOT analysis,
      • 11.5.5.4. Recent developments,
      • 11.5.5.5. strategies,
      • 11.5.5.6. financials (based on availability)
    • 11.5.6. Janssen Pharmaceuticals, Inc.
      • 11.5.6.1. Overview,
      • 11.5.6.2. Products & services,
      • 11.5.6.3. SWOT analysis,
      • 11.5.6.4. Recent developments,
      • 11.5.6.5. strategies,
      • 11.5.6.6. financials (based on availability)
    • 11.5.7. Mylan N.V.
      • 11.5.7.1. Overview,
      • 11.5.7.2. Products & services,
      • 11.5.7.3. SWOT analysis,
      • 11.5.7.4. Recent developments,
      • 11.5.7.5. strategies,
      • 11.5.7.6. financials (based on availability)
    • 11.5.8. Novartis AG
      • 11.5.8.1. Overview,
      • 11.5.8.2. Products & services,
      • 11.5.8.3. SWOT analysis,
      • 11.5.8.4. Recent developments,
      • 11.5.8.5. strategies,
      • 11.5.8.6. financials (based on availability)

12. Strategic Recommendations

List of Tables

  • Table 1: Global Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2015-2034
  • Table 2: Global Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Disease Indication, 2015-2034
  • Table 3: Global Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2015-2034
  • Table 4: Global Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Region, 2021-2034
  • Table 5: North America Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2021-2034
  • Table 6: North America Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 7: North America Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Antiviral Drugs Market Revenue (US$ Mn) Forecast, By Country, 2021-2034
  • Table 9: Europe Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2021-2034
  • Table 10: Europe Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 11: Europe Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Antiviral Drugs Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2021-2034
  • Table 14: Asia Pacific Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 15: Asia Pacific Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Antiviral Drugs Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Latin America Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2021-2034
  • Table 18: Latin America Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 19: Latin America Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Latin America Antiviral Drugs Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2021-2034
  • Table 22: Middle East & Africa Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 23: Middle East & Africa Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Middle East & Africa Antiviral Drugs Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Table 1: Global Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2015-2034
  • Table 2: Global Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Disease Indication, 2015-2034
  • Table 3: Global Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2015-2034
  • Table 4: Global Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Region, 2021-2034
  • Table 5: North America Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2021-2034
  • Table 6: North America Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 7: North America Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Antiviral Drugs Market Revenue (US$ Mn) Forecast, By Country, 2021-2034
  • Table 9: Europe Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2021-2034
  • Table 10: Europe Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 11: Europe Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Antiviral Drugs Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2021-2034
  • Table 14: Asia Pacific Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 15: Asia Pacific Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Antiviral Drugs Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Latin America Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2021-2034
  • Table 18: Latin America Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 19: Latin America Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Latin America Antiviral Drugs Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2021-2034
  • Table 22: Middle East & Africa Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 23: Middle East & Africa Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Middle East & Africa Antiviral Drugs Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034